Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Key Stats

• Today's Range: $1.24 to $1.31
• 50-Day Range: $1.30 to $2.02
• 52-Week Range: $1.22 to $4.69
• Volume: 396,930 shs
• Average Volume: 226,224 shs
• Market Capitalization: $4.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Can-Fite BioPharma Stock Analysis - MarketRank™

Can-Fite BioPharma scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Can-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Can-Fite BioPharma is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Can-Fite BioPharma is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Can-Fite BioPharma has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CANF.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Can-Fite BioPharma does not currently pay a dividend.

Dividend Growth

Can-Fite BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CANF.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.23

News Sentiment

Can-Fite BioPharma has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.

Search Interest

5 people have searched for CANF on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

10 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.80% of the stock of Can-Fite BioPharma is held by insiders.

Percentage Held by Institutions

Only 21.00% of the stock of Can-Fite BioPharma is held by institutions.

CANF Stock Analysis - Frequently Asked Questions

How have CANF shares performed this year?

Can-Fite BioPharma's stock was trading at $1.6250 at the beginning of 2025. Since then, CANF shares have decreased by 22.5% and is now trading at $1.26.
View the best growth stocks for 2025 here.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) released its earnings results on Tuesday, November, 30th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $1.00. The firm had revenue of $0.25 million for the quarter.

When did Can-Fite BioPharma's stock split?

Can-Fite BioPharma's stock reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Can-Fite BioPharma's major shareholders?

Top institutional investors of Can-Fite BioPharma include Rhumbline Advisers (1.08%).

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +1,011.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $667,000.00
• Price / Sales: 6.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 3,540,000
• Free Float: N/A
• Market Cap: $4.46 million
• Optionable: Not Optionable
• Beta: 1.37